Danaher (NYSE:DHR) had its price target raised by investment analysts at Credit Suisse Group from $260.00 to $264.00 in a research report issued on Thursday. The firm currently has an “outperform” rating on the conglomerate’s stock. Credit Suisse Group’s target price would suggest a potential upside of 10.07% from the stock’s current price.
Other analysts have also issued research reports about the stock. The Goldman Sachs Group assumed coverage on shares of Danaher in a research report on Wednesday, December 2nd. They issued a “buy” rating and a $250.00 price objective on the stock. Wells Fargo & Company reissued a “buy” rating and set a $234.00 price target on shares of Danaher in a research report on Tuesday, September 29th. Royal Bank of Canada cut Danaher from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $273.00 to $234.00 in a report on Wednesday, November 25th. Needham & Company LLC lifted their target price on Danaher from $209.00 to $272.00 in a research report on Tuesday, October 27th. Finally, KeyCorp started coverage on Danaher in a research report on Monday, November 9th. They set an “overweight” rating and a $280.00 price target for the company. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $225.38.
Shares of Danaher stock opened at $239.84 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.08 and a quick ratio of 1.68. The firm has a market cap of $170.38 billion, a price-to-earnings ratio of 48.55, a price-to-earnings-growth ratio of 2.83 and a beta of 0.74. The stock’s 50-day moving average is $225.79 and its 200-day moving average is $213.85. Danaher has a one year low of $119.60 and a one year high of $248.32.
In related news, EVP Daniel L. Comas sold 54,402 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $233.25, for a total value of $12,689,266.50. Following the transaction, the executive vice president now owns 130,161 shares in the company, valued at approximately $30,360,053.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Robert S. Lutz sold 24,594 shares of the stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $233.19, for a total transaction of $5,735,074.86. Following the completion of the transaction, the chief accounting officer now directly owns 43,544 shares in the company, valued at $10,154,025.36. The disclosure for this sale can be found here. Insiders have sold a total of 107,385 shares of company stock valued at $25,081,562 in the last ninety days. Insiders own 11.70% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Provident Wealth Management LLC bought a new stake in Danaher in the 3rd quarter worth $27,000. Price Wealth LLC lifted its position in Danaher by 75.6% during the 3rd quarter. Price Wealth LLC now owns 137 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 59 shares during the period. Newfound Research LLC purchased a new stake in Danaher in the third quarter worth about $37,000. Atlas Private Wealth Management bought a new position in shares of Danaher during the third quarter valued at approximately $41,000. Finally, Oakworth Capital Inc. lifted its holdings in shares of Danaher by 48.9% during the third quarter. Oakworth Capital Inc. now owns 198 shares of the conglomerate’s stock valued at $43,000 after purchasing an additional 65 shares during the last quarter. 69.16% of the stock is owned by institutional investors and hedge funds.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Bid-Ask Spread
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.